Treatment of leprosy/Hansen's disease in the early 21st century

Dermatologic Therapy

Volumn 22, Issue 6, 2009, Pages 518-537

  Worobec, Sophie M ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Borderline; Erythema nodosum leprosum; Hansen's disease; Lepromatous; Leprosy; Lucio phenomenon; Multibacillary; Multiple drug therapy; Paucibacillary; Reversal reactions; Tuberculoid

Indexed keywords

ACETYLSALICYLIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; AZATHIOPRINE; BCG VACCINE; CARBAMAZEPINE; CETIRIZINE; CLARITHROMYCIN; CLOFAZIMINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; ESTROGEN; HYDROXYCHLOROQUINE; INFLIXIMAB; LEVOFLOXACIN; MACROLIDE; METHADONE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OFLOXACIN; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PENTOXIFYLLINE; PREDNISONE; PROTEINASE INHIBITOR; RIFAMPICIN; THALIDOMIDE;

ACUTE KIDNEY FAILURE; ADVERSE DRUG REACTION; AGRANULOCYTOSIS; ANEMIA; ANTIBIOTIC THERAPY; ARTHRITIS; BACTERIAL TRANSMISSION; BACTERIUM IDENTIFICATION; BCG VACCINATION; BONE MARROW SUPPRESSION; BORDERLINE LEPROSY; BRAIN EDEMA; CHILL; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE CLASSIFICATION; DIZZINESS; DRUG ERUPTION; DRUG FATALITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDEMIC DISEASE; EOSINOPHILIA; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM LEPROSUM; FLU LIKE SYNDROME; GASTROINTESTINAL OBSTRUCTION; GENE LOCUS; GENETIC ASSOCIATION; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HEMOLYSIS; HISTOPATHOLOGY; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; ICHTHYOSIS; INFECTION CONTROL; INFECTION RATE; INFECTION RESISTANCE; LACTATION; LEPROMATOUS LEPROSY; LEPROSY; LIVER TOXICITY; METHEMOGLOBINEMIA; MULTIBACILLARY LEPROSY; MULTIPLE MYELOMA; MYALGIA; MYCOBACTERIUM LEPRAE; NAUSEA; NERVE INJURY; NEUTROPENIA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PAUCIBACILLARY LEPROSY; PERIPHERAL NEUROPATHY; PHOCOMELIA; PHOTOSENSITIVITY; PHOTOTOXICITY; PREGNANCY; PROMOTER REGION; PUBLIC HEALTH PROBLEM; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SHOCK; SIDE EFFECT; SKIN DEFECT; SPLEEN INFARCTION; SPLEEN RUPTURE; SWEATING; TEAR FLOW; TERATOGENICITY; THROMBOCYTOPENIA; TUBERCULOID LEPROSY; TUBERCULOSIS; UNITED STATES; URINE COLOR; VENOUS THROMBOEMBOLISM; WORLD HEALTH ORGANIZATION; XEROSIS;

HUMANS; LEPROSTATIC AGENTS; LEPROSY;

EID: 70449389204     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2009.01274.x     Document Type: Review

References (81)

1. Jopling WH, McDougall AC. Handbook of Leprosy, 4th ed. Oxford : Hainemann Medical Books, 1988.
2. Shepard CC. The first decade in experimental leprosy. Bull W H O 1971 : 44 : 821 827.
3. Levy L, Ji B. The mouse foot-pad technique for cultivation of Mycobacterium leprae. Lepr Rev 2006 : 77 : 5 24.
4. Desikan KV, Sreevatsa. Extended studies on the viability of Mycobacterium Leprae outside the human body. Lepr Rev 1995 : 66 (4 287 295.
5. Davis WB, Schmidly DJ. The Mammals of Texas OnLine edition, 1994.
6. Lumpkin LR, Fox GF, Wolf JE. Leprosy in five armadillo handlers. J Am Acad Dermatol 1983 : 9 : 899 903.
7. Clark BM, Murray CK, Horvath LL, Deye GA, Rasnake MS, Longfield RN. Case-control study of armadillo contact and Hansen's disease. Am J Trop Med Hyg 2008 : 78 : 962 967.
8. Monot M, Honoré N, Garnier T, et al. On the origin of leprosy. Science 2005 : 308 : 1040 1042.
9. Truman, R. Leprosy in wild armadillos. Lepr Rev 2005 : 76 : 198 208.
10. Wilder-Smith EP, Van Brakel WH. Nerve damage in leprosy and its management. Nat Clin Pract Neurol 2008 : 4 (12 656 663.
11. Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay in the leprosy bacillus. Nature 2001 : 409 : 1007 1011.
12. Gelber RH. Ch 159 Leprosy (Hansen's Disease) In : Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson L, Loscalzo J, eds. Harrison's principles of internal medicine, 17th ed. New York : McGraw-Hill, 2008 : 1021 1027.
13. Scollard DM, Adams LB, Gillis TP, et al. The continuing challenges of leprosy. Clin Microbiol Rev 2006 : 19 (2 367 368.
14. Lockwood DNJ. Ch 29 Leprosy. In : Burns DA, Breathnach SM, Cox N, Griffiths CE, eds. Rook's textbook of dermatology Vol 2, 7th eds. Oxford : Blackwell Publishing, 2004 : 21.1 21.21.
15. Rea TH, Modlin RL. Ch 186 Leprosy. In : Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, eds. Fitzpatrick's dermatology in general medicine, 7th ed. New York : McGraw-Hill Professional, 2008 : 1786 1796.
16. Han XY, Seo Y-H, Sizer KC, et al. A new mycobacterium species causing diffuse lepromatous leprosy. Am J Clin Pathol 2008 : 130 : 856 864.
17. Ang P, Tay Y-K, Ng S-K, et al. Fatal Lucio's phenomenon in 2 patients with previously undiagnosed leprosy. J Am Acad Dermatol 2003 : 48 : 958 961.
18. Duncan ME, Melsom R, Pearson JMH, et al. A clinical and immunological study of four babies of mothers with lepromatous leprosy, two of whom developed leprosy in infancy. Int J Lepr 1983 51 : 7 17.
19. Porrit RJ, Olsen RS. Two simultaneous cases of leprosy developing in tattoos. Am J Pathol 1947 23 : 805 817.
20. Cree IA, Smith WC. Leprosy transmission and mucosal immunity: towards eradication? Lepr Rev 1998 69 : 112 121.
21. Kerr-Pontes LRS, Barreto ML, Evangelista CMN, et al. Socioeconomic, environmental, and behavioural risk factors for leprosy in North-east Brazil: results of a case-control study. Int J Epidemiol 2006 : 35 : 994 1000.
22. World Health Organization. WHO factsheet. http://www.who.int/lep/ strategy/wha/en/. Accessed June 16, 2009.
23. World Health Organization. WHO weekly epidemiological record. 2008 : 83 (33 293 300.
24. Lockwood DNJ. Leprosy elimination- a virtual phenomenon or a reality? BMJ 2002 : 324 : 1516 1518
25. http://www.who.int/lep/situation/en/. Accessed June 2, 2009.
26. Kumar B, Dogra SL. Leprosy. In : Rakel RE, Bope ET, eds. Conn's current therapy 2009. Philadelphia : Elsevier Health Sciences, 2008 : 97 103.
27. Moschella SL. An update on the diagnosis and treatment of leprosy. J Am Acad Dermatol 2004 : 51 : 417 426.
28. Meima A, Smith WC, van Oortmarssen GJ, et al. The future incidence of leprosy: a scenario analysis. Bull World Health Organ 2004 : 82 : 373 380.
29. Smith C Richardus JH. Leprosy strategy is about control, not eradication. Lancet 2008 : 371 : 969 970.
30. Meima A, Irgens LM, van Oortmarssen GJ, et al. Disappearance of leprosy from Norway: an exploration of critical factors using an epidemiological modelling approach. Int J Epidemiol 2002 : 31 : 991 1000.
31. A summary of Hansen's disease in the United States-2006. U.S. Department of Health and Human Services Health Resources and Services Administration National Hansen's Disease Program. http://www.hrsa.gov/hansens/data2006/. Accessed June 2, 2009.
32. World Health Organization. WHO weekly epidemiological record. 2008 : 83 (50 449 460.
33. Chakravartti MR, Vogel FA. A twin study on leprosy. In : Becker PE, ed. Topics in human genetics Vol 1. Stuttgart : Georg Thieme, 1973 : 1 123.
34. Mohammed AP, Ramanujam K. Leprosy in twins. Int J Lepr 1966 : 34 : 405 406.
35. Abel L, Sanchez FO, Oberti J, et al. Susceptibility to leprosy is linked to the human NRAMP1 Gene. J Infect Dis 1998 : 177 : 133 145.
36. Mira MT, Alcais A, Nguyen VT, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 2004 : 427 : 636 640.
37. Buschman E, Skameme E. Linkage of leprosy susceptibility to Parkinson's disease genes. Int J Lepr Other Mycobact Infect 2004 : 72 : 169 170.
38. Bochud P-Y, Sinsimer D, Aderem A, et al. Polymorphisms in Toll-like receptor 4 (TLR4) are associated with protection against leprosy. Eur J Clin Microbiol and Infect Dis 2009 : 28 : 1055 1065.
39. Girdhar A, Mishra B, Lavania RK, et al. Leprosy in infants-report of two cases. Int J Lepr 1989 : 57 (2 472 475.
40. Krishna Moorthy KV, Desikan KV. Indeterminate leprosy in an infant. Lepr Rev 2006 : 77 : 377 380.
41. http://www.who.int/lep/situation/americas/en/index.html. Accessed May 30, 2009.
42. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 1966 : 34 : 255 273.
43. Boggild AK, Keystone JS, Kain KC. Leprosy: a primer for Canadian physicians. Can Med Assoc J 170 (1 71 78.
44. Walker SL, Lockwood DNJ. The clinical and immunological features of leprosy. Br Med Bull 2006 : 1 19.
45. Pfaltzgraff RE, Bryceson A. Clinical leprosy. In : Hastings RC, ed. Leprosy, 1st ed. Edinburgh : Churchill Livingstone, 1985 : 134 176.
46. Ridley D. Skin biopsy in leprosy. Histologic interpretation and clinical application. Documenta Geigy. Basel, Switzerland : Ciba-Geigy Limited, 1977 : 13.
47. James WD, Berger TG, Elston DM. Chapter 17 Hansen's disease. In Andrews' diseases of the skin: clinical dermatology, 10th ed. Saunders W B Co., 2005 : 343 352.
48. Barton RPE. Ear, nose and throat involvement in leprosy. In : Hastings RC, ed. Leprosy. Edinburgh : Churchill Livingstone, 1985 : 243 252.
49. Lynch P. Greater auricular nerve in diagnosis of leprosy. Br Med J 1978 : iv : 1340.
50. http://www.who.int/lep/mdt/regimens/en/index.html. Accessed June 14, 2009.
51. Ramu G. Single-dose rifampicin, oflaxicin and minocycline (ROM) therapy for single leprosy lesions. Lepr Rev 1998 69 (1 78 82.
52. Katoch VM. Is there a microbiological rationale for single-dose treatment of leprosy? Lepr Rev 1998 : 69 : 2 5.
53. World Health Organization. Global strategy for further reducing the leprosy burden and sustaining leprosy control activities 2006-2010; Operational Guidelines. Regional Office for South-East Asia, New Delhi, 2006.
54. King K, Browning JC, Metry DW, et al. Leprosy and international adoption. Pediatr Infect Dis J 2009 : 28 (4 322 325.
55. http://www.hrsa.gov/hansens/clinical/regimens.htm. Accessed June 12, 2009.
56. Litt JZ. Litt's drug eruption reference manual, 15th ed. New York : Informa Healthcare, 2009 : 182 183.
57. Gupta A, Sakhuja V, Gupta KL, et al. Intravascular hemolysis and acute renal failure following intermittent rifampin therapy. Int J Lepr Other Mycobact Dis 1992 : 60 : 185 188.
58. John SS. Fixed drug eruption due to rifampin. Lepr Rev 1998 : 69 : 397 399.
59. Jacobsen, RR. Treatment of leprosy. In : Hastings RC, ed. Leprosy, 2nd ed. Edinburgh : Churchill Livingstone, 1994 : 317 349.
60. Britton W. The management of leprosy reversal reactions. Lepr Rev 1998 : 69 : 225 234.
61. Burdick AE, Ramirez CC. The role of mycophenolate mofetil in the treatment of leprosy reactions. Int J Lepr Other Mycobact Dis 2005 : 73 : 127 128.
62. Biosca G, Casallo S, Lopez-Velez R. Methotrexate treatment for type 1 (reversal) leprosy reactions. Clin Infect Dis 2007 : 45 : e7 e9.
63. Couppie P, Abel S, Voinchet H, et al. Immune reconstitution inflammatory syndrome associated with HIV and leprosy. Arch Dermatol 2004 : 140 : 997 1000.
64. Kar HK, Sharma P, Bhardwaj M. Borderline tuberculoid leprosy with upgrading Type 1 reaction in a HIV seropositive patient, after antiretroviral therapy: an Immune Reconstitution Inflammatory Syndrome. Lepr Rev 2009 : 80 : 85 88.
65. Dolev J, Reyter I, Maurer T. Treatment of recurring cutaneous drug reactions in patients with human immunodeficiency virus 1 infection: a series of 3 cases. Arch Dermatol 2004 : 140 : 1051 1053.
66. Ling TC, Prescott RJ, Daly M. Painful skin nodules and epididymo-orchitis. Arch Dermatol 2002 : 138 : 1607 1612.
67. Faber WR, Jensema AJ, Goldschmidt WFM. Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med 2006 : 355 (7 739.
68. Kar BR, Babu R. Methotrexate in resistant ENL. Int J Lepr Other Mycobact Dis 2004 : 72 : 480 482.
69. Scollard DM, Joyce MP. Leprosy (Hansen's Disease). In : Rakel RE, Bope ET, eds. Conn's current therapy, 55th ed. St. Louis : Saunders Elsevier, 2003 : 101 105.
70. Lockwood D. Ch. 18 Leprosy. In Gill G, Beeching N, eds. Lecture notes: tropical medicine, 6th ed. Oxford : Blackwell Publishing, 2009 : 171 182.
71. World Health Organization. WHO model prescribing information: drugs used in Leprosy. 2008. http://apps.who.int/medicinedocs/en/d/Jh2988e/10.html. Accessed June 20, 2009.
72. Duncan ME, Melson R, Pearson JMH, Ridley DS. The association of pregnancy and leprosy.1. New cases, relapse of cured patients and deterioration of patients on treatment during pregnancy and lactation-results of a prospective study of 154 pregnacies in 147 Ethiopian women. Lepr Rev 1981 : 52 : 245 262.
73. Lockwood DNJ, Sinha HH. Pregnancy and leprosy. Int J Lepr Other Mycobact Dis 1999 : 67 : 6 12.
74. Duncan ME, Miko T, Howe R, et al. Growth and development of children of mothers with leprosy and healthy controls. Ethiop Med J 2007 : 45 (Suppl. 1 9 23.
75. Dawe S, Lockwood DNJ, Creamer D. A case of post-partum borderline tuberculoid leprosy complicated by a median nerve abscess, peptic ulceration and rifampicin-induced haemolytic renal failure. Lepr Rev 2004 : 75 : 181 187.
76. Scollard DM, Smith T, Bhoopat L, et al. Epidemiologic characteristics of leprosy reactions. Int J Lepr Other Mycobact Dis 1994 : 62 : 559 567.
77. Scollard DM, Joyce MP, Gillis TP. Development of leprosy and Type 1 leprosy reactions after treatment with infliximab: a report of two cases. Clin Infect Dis 2006 : 43 : e19 e22.
78. Camacho ID, Valencia I, Rivas MP, et al. Type 1 leprosy reaction manifesting after discontinuation of adalimumab therapy. Arch Dermatol 2009 : 145 (3 349 351.
79. Office of Public Health, Louisiana Dept. of Health & Hospitals; Infectious Disease Epidemiology Section. Hansen's Disease (Leprosy), Oct. 8, 2004.
80. http://www.hrsa.gov/hansens/history.htm. Accessed June 9, 2009.
81. http://www.fortyandeight.org/star.htm. Accessed April 29, 2009.